StockData
Entera Bio Ltd. logo

Entera Bio Ltd. (ENTX) stock

ENTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 6/30
$3.26+0.26 (+8.67%)

Close on Nov 18, 2026Market cap $564.44MP/E –Yield –

Entera Bio free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Entera Bio's free cash flow for the twelve months ending Jun 30, 2026 was -$10.96M. For fiscal 2025 it was -$7.48M. The highest annual figure on record is -$3.18M in fiscal 2016.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$7.48M–
FY2024Dec 31, 2024-$6.82M–
FY2023Dec 31, 2023-$7.33M–
FY2022Dec 31, 2022-$12.55M–
FY2021Dec 31, 2021-$9.08M–
FY2020Dec 31, 2020-$10.61M–
FY2019Dec 31, 2019-$8.96M–
FY2018Dec 31, 2018-$9.86M–
FY2017Dec 31, 2017-$4.58M–
FY2016Dec 31, 2016-$3.18M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$3.47M–
Q1 FY2026Mar 31, 2026-$3.09M–
Q4 FY2025Dec 31, 2025-$1.86M–
Q3 FY2025Sep 30, 2025-$2.55M–
Q2 FY2025Jun 30, 2025-$1.66M–
Q1 FY2025Mar 31, 2025-$1.41M–
Q4 FY2024Dec 31, 2024-$1.47M–
Q3 FY2024Sep 30, 2024-$2.15M–
Q2 FY2024Jun 30, 2024-$1.34M–
Q1 FY2024Mar 31, 2024-$1.86M–
Q4 FY2023Dec 31, 2023-$2.62M–
Q3 FY2023Sep 30, 2023-$1.53M–
Q2 FY2023Jun 30, 2023-$1.56M–
Q1 FY2023Mar 31, 2023-$1.62M–
Q4 FY2022Dec 31, 2022-$2.01M–
Q3 FY2022Sep 30, 2022-$2.87M–
Q2 FY2022Jun 30, 2022-$2.85M–
Q1 FY2022Mar 31, 2022-$4.82M–
Q4 FY2021Dec 31, 2021-$2.52M–
Q3 FY2021Sep 30, 2021-$2.12M–
Q2 FY2021Jun 30, 2021-$2.12M–
Q1 FY2021Mar 31, 2021-$2.32M–

More Entera Bio figures

See a number that looks wrong?